Type 2 Diabetes

A proper baseline assessment for GLP-1 therapy has become a critical yet sometimes overlooked step in modern diabetes care. In fast-moving clinical environments, especially with the rise of telehealth, providers may feel pressure to initiate GLP-1 therapy quickly. However, skipping essential baseline evaluations can lead to missed risks, poor outcomes, …

What happens when a patient walks into your clinic and their diabetes simply doesn’t fit the usual mold? In many cases, clinicians rely on well-established categories like Type 1 or Type 2 diabetes. However, diagnosing atypical forms of diabetes is becoming increasingly important as more patients present with mixed or …

GLP-1 therapies are becoming an important focus in peripheral artery disease, especially as clinicians look beyond glucose control to improve outcomes in high-risk patients. People with diabetes and peripheral artery disease often face a difficult path, marked by poor circulation, delayed wound healing, and a higher risk of amputation. While …

Disease progression in patients using GLP-1 therapies is becoming a critical topic as these medications continue to reshape diabetes care. While GLP-1 receptor agonists improve glycemic control and support weight loss, could they also be hiding deeper metabolic decline? Much like a polished surface that conceals underlying cracks, improved lab …

Telehealth prescribing of GLP-1 medications is rapidly reshaping how diabetes and weight management care is delivered. But as access expands, an important question emerges: who is truly managing patient care? Like a relay race without a clear handoff, patients often move between providers, platforms, and pharmacies without consistent oversight. As …

The risk of side effects with GLP-1 therapies varies widely among patients, yet treatment decisions often overlook this variability. Why do some patients tolerate GLP-1 receptor agonists with ease while others discontinue early? Much like how individuals respond differently to diet or exercise, medication tolerance is influenced by a mix …

The rise of newer incretin-based therapies is changing how clinicians think about diabetes care. But are GLP-1 receptor agonists already being challenged by this next wave of incretin therapy? While these medications have transformed treatment in recent years, newer multi-agonist therapies are gaining attention. As a result, healthcare providers are …

What does success really look like with GLP-1 therapy in 2026? Is it simply lowering A1C, or are clinicians now aiming for something more sustainable like remission or long-term maintenance? As GLP-1 receptor agonists continue to transform diabetes care, the conversation is shifting beyond short-term outcomes. Today, defining clear and …

GLP-1 dose escalation is quickly becoming a central topic in diabetes care, especially as higher dosing strategies gain traction. But are we truly entering a high-dose era, or simply refining how we use these powerful agents? As clinicians face patients who plateau on standard regimens, the question becomes not just …

Managing type 2 diabetes today can feel like navigating a moving target. As new guidelines shift toward personalized, risk-based care, many clinicians ask the same question: how can a diabetes risk stratification approach be applied effectively in daily practice? This evolving approach is not just theoretical. Instead, it offers a …